Patient-reported Outcomes of Treatment and Adverse Effects Following Acute Lymphoblastic Leukemia: a Low- and Middle-income Country Cross-sectional Study

Overview

Journal Hematol Transfus Cell Ther

Specialty Hematology

Date 2024 Aug 12

PMID 39129098

Authors

Eduardo Cerello Chapchap

Nina Melo

Denise Martins

Maria Lucia Lee

Nelson Hamerschlak

Affiliations

Soon will be listed here.

Abstract

Introduction: The scenario of adult patients with acute lymphoblastic leukemia treated in Brazil has not been well described yet.

Methods: Four hundred patients diagnosed with acute lymphoblastic leukemia from 1981 to 2019, registered in the Brazilian lymphoma and leukemia association (ABRALE) or their caregivers were interviewed by telephone to evaluate patient-reported perceptions of diagnosis, treatment and adverse effects.

Results: Overall, 203 were male with a mean age of 15.7 years and median follow-up of 6.2 years. Main presenting symptoms were fever (39 %), bleeding/ecchymosis (38 %), intense fatigue (30 %), and musculoskeletal pain (28 %). The proportion of patients diagnosed within one week of symptoms onset differed between public (17.9 %) and private healthcare (31.1 %; p-value = 0.019). Additionally, diagnostic difficulties were higher in public care: 35 % versus 22.6 % (p-value = 0.034). Only 36 patients were able to report their treatment protocols; from a list of eight reported protocols, the most common were the Brazilian Childhood Cooperative Group for Treatment of Acute Lymphoblastic Leukemia in Children (GBTLI - 10/27.8 %) and Berlin-Frankfurt-Münster (BFM - 8/22.2 %). Seventy patients (17.5 %) required treatment modification, 37.1 % due to severe adverse effects; 21.7 % received short treatment duration (≤6 months) and 16 % proceeded to allogeneic hematopoietic stem cell transplantation with 17/64 (27 %) reporting difficulties in this step, characterized as >3 months delay. Indication for transplantation was related to minimal residual disease and cranial radiotherapy; 41.7 % reported treatment-related adverse effects (range: 1-6), in particular: mood disorders (26.3 %), neurologic deficit (13.8 %), cognitive/memory impairment (12 %), and lung disease (15 %). Risk factors for adverse effects were age, indication of transplantation and living in a large city. Treatment disparities such as diagnostic and transplantation delays remain challenges in these patients.

Conclusions: Urgent interventions are needed to optimize healthcare and reduce adverse effects, especially in adolescent and young adult patients.

References

Wasilewska E, Kuziemski K, Niedoszytko M, Kaczorowska-Hac B, Niedzwiecki M, Malgorzewicz S . Impairment of lung diffusion capacity-a new consequence in the long-term childhood leukaemia survivors. Ann Hematol. 2019; 98(9):2103-2110. PMC: 6700051. DOI: 10.1007/s00277-019-03745-4. View

Brix N, Hasle H, Rosthoj S, Herlin T . Characteristics of children with acute lymphoblastic leukemia presenting with arthropathy. Clin Rheumatol. 2018; 37(9):2455-2463. DOI: 10.1007/s10067-018-4034-1. View

Wilson C, Howell C, Partin R, Lu L, Kaste S, Mulrooney D . Influence of fitness on health status among survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018; 65(11):e27286. PMC: 6150801. DOI: 10.1002/pbc.27286. View

Larsen E, Devidas M, Chen S, Salzer W, Raetz E, Loh M . Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. J Clin Oncol. 2016; 34(20):2380-8. PMC: 4981974. DOI: 10.1200/JCO.2015.62.4544. View

Savage E, Riordan A, Hughes M . Quality of life in children with acute lymphoblastic leukaemia: a systematic review. Eur J Oncol Nurs. 2008; 13(1):36-48. DOI: 10.1016/j.ejon.2008.09.001. View

Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H . Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2009; 24(2):265-84. DOI: 10.1038/leu.2009.257. View

Fogliatto L, Bittencourt H, Nunes A, Salenave P, Silva G, Daudt L . Outcome of treatment in adult acute lymphoblastic leukemia in southern Brazil using a modified german multicenter acute lymphoblastic leukemia protocol. Acta Haematol. 2002; 107(4):203-7. DOI: 10.1159/000058315. View

Campos L, Goldstein S, Santiago R, de Jesus A, Cristofani L, Filho V . [Musculoskeletal involvement as a first manifestation of neoplasm disease]. Rev Assoc Med Bras (1992). 2008; 54(2):132-8. DOI: 10.1590/s0104-42302008000200015. View

Stock W, Luger S, Advani A, Yin J, Harvey R, Mullighan C . A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019; 133(14):1548-1559. PMC: 6450431. DOI: 10.1182/blood-2018-10-881961. View

10.

Moghrabi A, Levy D, Asselin B, Barr R, Clavell L, Hurwitz C . Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2006; 109(3):896-904. PMC: 1785142. DOI: 10.1182/blood-2006-06-027714. View

11.

Brandalise S, Viana M, Pinheiro V, Mendonca N, Lopes L, Pereira W . Shorter Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia: The Experience of the Prospective, Randomized Brazilian GBTLI ALL-93 Protocol. Front Pediatr. 2016; 4:110. PMC: 5066157. DOI: 10.3389/fped.2016.00110. View

12.

Dang-Tan T, Franco E . Diagnosis delays in childhood cancer: a review. Cancer. 2007; 110(4):703-13. DOI: 10.1002/cncr.22849. View

13.

Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E . Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27(6):911-8. DOI: 10.1200/JCO.2008.18.6916. View

14.

Klein-Geltink J, Pogany L, Barr R, Greenberg M, Mery L . Waiting times for cancer care in Canadian children: impact of distance, clinical, and demographic factors. Pediatr Blood Cancer. 2004; 44(4):318-27. DOI: 10.1002/pbc.20156. View

15.

Burger B, Zimmermann M, Mann G, Kuhl J, Loning L, Riehm H . Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003; 21(2):184-8. DOI: 10.1200/JCO.2003.04.096. View

16.

de Oliveira B, Valadares M, Silva M, Viana M . Compliance with a protocol for acute lymphoblastic leukemia in childhood. Rev Bras Hematol Hemoter. 2012; 33(3):185-9. PMC: 3415741. DOI: 10.5581/1516-8484.20110051. View

17.

Bergfelt Lennmyr E, Karlsson K, Abrahamsson M, Ebrahim F, Lubking A, Hoglund M . Introducing patient-reported outcome in the acute leukemia quality registries in Sweden. Eur J Haematol. 2020; 104(6):571-580. DOI: 10.1111/ejh.13399. View

18.

Rytting M, Jabbour E, Jorgensen J, Ravandi F, Franklin A, Kadia T . Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016; 91(8):819-23. PMC: 5558853. DOI: 10.1002/ajh.24419. View

19.

Silva Junior W, Medina A, Eiko Yamakawa P, Buccheri V, Velloso E, Rocha V . Treating Adult Acute Lymphoblastic Leukemia in Brazil-Increased Early Mortality Using a German Multicenter Acute Lymphoblastic Leukemia-based regimen. Clin Lymphoma Myeloma Leuk. 2018; 18(6):e255-e259. DOI: 10.1016/j.clml.2018.03.001. View

20.

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View